Xenon Pharmaceuticals Inc.

XENEPharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Phase 32

Phase 21

By Therapeutic Area

top 2

Psychiatry

150%

Neurology

150%

R&D Momentum

38/100

Pipeline Velocity

6/100

Trial Completion Rate

86/100

Pipeline Concentration

50/100

Pipeline Freshness

73/100

Strategic Signals

↗Active in Psychiatry but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 12, 2026

Enrolling by invitation

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy

Sep 9, 2026

Recruiting

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder

Earlier

Sep 4, 2026TrialA Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder

Sep 3, 2026TrialA Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Sep 3, 2026TrialA Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression

Aug 11, 2026TrialA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Aug 4, 2026TrialA Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder

May 9, 2023TrialA Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

4 more events

Nov 18, 2022TrialA Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

May 19, 2022TrialA Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Aug 17, 2021TrialAn Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Jul 14, 2021TrialSingle-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Therapeutic Focus

NeurologyPsychiatry

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)